All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Natural Killer (NK) cells partly mediate immune responses against Myelodysplastic Syndrome (MDS) and this can potentially affect disease progression. NK cells express both activating and inhibitory Killer Immunoglobulin-like Receptors (KIRs) that interact and mediate NK effector function. Based on the number of inherited KIR genes, individuals can be divided into two haplotype groups: haplotype A (comprises of five inhibitory KIR genes and a single Activating KIR [aKIR] gene) and haplotype B (comprises various combinations of aKIR genes and inhibitory KIR genes).
Dr Kate Stringaris from Hammersmith Hospital, Imperial College, London, and colleagues recently published the findings of their study, which is on the variations of aKIR gene content and haplotype in MDS and their association to progression to Acute Myeloid Leukemia (AML) and survival. The data obtained were first published ahead of print on 19 October 2016 in Blood.
The authors concluded by stating that their findings show an association between aKIR gene content and MDS-AML transformation. This association could be used to identify a subgroup of MDS patients with a high risk of disease progression and poor outcome who would benefit from adoptive NK cell therapy. A poster based on their findings was presented at a session held on the 5 December 2016 at the American Society of Hematology Meeting in San Diego.
Myelodysplastic syndromes (MDSs) are a group of hematopoietic disorders affecting the myeloid lineage, characterized by cytopenias and clonal evolution to acute myeloid leukemia (AML). We hypothesized that natural killer (NK) cells and their activating killer immunoglobulin-like receptors (aKIRs) influence the immune surveillance and clinical outcome of patients with MDSs. Here, we first examined the distribution of aKIR genes and haplotype in 2 independent cohorts of MDS and AML patients. The median number of aKIR genes was lower in MDS patients than healthy controls (2 vs 3 genes; P = .001), and lower in patients with secondary AML (progressed from MDSs) compared with de novo AML patients (2 vs 3; P = .008) and healthy controls (2 vs 3; P = .006). In a multivariate analysis, the presence of KIR haplotype A (characterized by low aKIR content 0-1) independently predicted a higher risk of conversion to AML (relative risk [RR] with 95% confidence interval [CI], 2.67 [1.13-6.71]; P = .02) and worse adjusted progression-free survival (RR with 95% CI, 2.96 [1.59-5.52]; P = .001) and overall survival (2.25 [1.17-4.31]; P = .02), compared with KIR haplotype B (multiple aKIR genes). These novel findings may help to identify MDS patients with a high risk of disease progression who would likely benefit from adoptive NK-cell therapy.
References